Back to Search
Start Over
Alkermes presents data from phase 1b study of ALKS 2680
- Source :
- The Fly. June 3, 2024
- Publication Year :
- 2024
-
Abstract
- Alkermes announced new data from the full narcolepsy type 1 cohort of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral orexin 2 receptor agonist in [...]
- Subjects :
- Narcolepsy
Business
News, opinion and commentary
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.796123274